Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The N-linked glycan at Asparagine 297 (Asn297) is a critical structural component located within the CH2 domain of the Fc region of Immunoglobulin G (IgG) (Jefferis, 2009). This biantennary complex-type oligosaccharide is essential for maintaining the open conformation of the Fc region, which is required for binding to Fc gamma receptors (FcγRs) and the C1q complement protein (Pereira et al., 2018). Variations in the glycan's composition—specifically the presence of fucose, galactose, sialic acid, and bisecting N-acetylglucosamine—act as a molecular switch to modulate the antibody's pro- or anti-inflammatory activities (Wang & Amin, 2014). In oncology, therapeutic antibodies are often glycoengineered to lack core fucose (afucosylation) at Asn297, which significantly enhances their affinity for FcγRIIIa and boosts antibody-dependent cellular cytotoxicity (ADCC) against tumor cells (Pereira et al., 2018). Conversely, in autoimmune diseases, the enzymatic removal of this glycan by bacterial enzymes like Endoglycosidase S (EndoS) is being explored as a strategy to neutralize pathogenic autoantibodies by preventing them from activating effector cells (Sjögren et al., 2015). Consequently, the Asn297 glycan is a central target for optimizing the efficacy and safety of monoclonal antibody therapies.
Modulation of Fc gamma receptor (FcγR) affinity through glycoengineering (e.g., afucosylation) or enzymatic cleavage to alter immune effector functions (Jefferis, 2009; Pereira et al., 2018).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin G Fc region N-linked glycan at Asparagine 297 (IgG Fc Asn297 glycan).